Last Updated : November 7, 2024
Details
FilesGeneric Name:
ruxolitinib
Project Status:
Active
Therapeutic Area:
Nonsegmental vitiligo
Manufacturer:
Incyte Biosciences Canada Corporation
Call for patient/clinician input open:
Brand Name:
Opzelura
Project Line:
Reimbursement Review
Project Number:
SR0835-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Topical treatment of
nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Topical treatment of
nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 05-Sep-24 |
|---|---|
| Call for patient/clinician input closed | 28-Oct-24 |
| Submission received | 17-Oct-24 |
| Submission accepted | 31-Oct-24 |
| Review initiated | 01-Nov-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 31-Jan-25 |
| Deadline for sponsors comments | 11-Feb-25 |
| CADTH review report(s) and responses to comments provided to sponsor | 13-Mar-25 |
| Expert committee meeting (initial) | 26-Mar-25 |
| Draft recommendation issued to sponsor | April 07, 2025 To April 09, 2025 |
| Draft recommendation posted for stakeholder feedback | 17-Apr-25 |
| End of feedback period | 05-May-25 |
Files
Last Updated : November 7, 2024